Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness.
about
Active metabolites as antidepressant drugs: the role of norquetiapine in the mechanism of action of quetiapine in the treatment of mood disordersFluoxetine Facilitates Fear Extinction Through Amygdala EndocannabinoidsThe effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4'-hydroxylase activity in human liver microsomesClinical course and toxicokinetic data following isolated citalopram overdose in an infant.Citalopram in the treatment of depression.Citalopram--a review of pharmacological and clinical effects.Tolerability and safety of fluvoxamine and other antidepressants.Serotonergic/glutamatergic interactions: potentiation of phencyclidine-induced stimulus control by citalopram.The SSRIs: advantages, disadvantages and differences.Early-life exposure to the SSRI paroxetine exacerbates depression-like behavior in anxiety/depression-prone rats.Effects of chronic treatment with escitalopram or citalopram on extracellular 5-HT in the prefrontal cortex of rats: role of 5-HT1A receptorsStereo-specific LC and LC-MS bioassays of antidepressants and psychotics.Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy SwedesUse of antidepressant drugs in transplant recipients.Pharmacokinetics and interactions of headache medications, part II: prophylactic treatments.Predictive factors for generalized seizures after deliberate citalopram overdoseAssociation of citalopram with congenital anomalies: A meta-analysisMaternal Pharmacokinetics and Fetal Disposition of (±)-Citalopram during Mouse Pregnancy.Effect of microemulsions on transdermal delivery of citalopram: optimization studies using mixture design and response surface methodology.Synthesis and Antimicrobial Screening of Novel 4-Substituted Phenyl-5-[1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-yl]-2H-1,2,4-triazole-3-thiones.Chronic citalopram treatment elevates serotonin synthesis in flinders sensitive and flinders resistant lines of rats, with no significant effect on Sprague-Dawley rats.5-HT 1A/1B receptor-mediated effects of the selective serotonin reuptake inhibitor, citalopram, on sleep: studies in 5-HT 1A and 5-HT 1B knockout mice.[18F]altanserin binding to human 5HT2A receptors is unaltered after citalopram and pindolol challenge.Impulsive-aggressive traits, serotonin function, and alcohol-enhanced aggression.Safety and efficacy of citalopram in the treatment of premature ejaculation: a double-blind placebo-controlled, fixed dose, randomized study.Possible central anticholinergic syndrome following transdermal scopolamine in an ambulatory surgery patient.Antidepressant drugs inhibit a glial 5-hydroxytryptamine transporter in rat brain.Biperiden selectively induces memory impairment in healthy volunteers: no interaction with citalopram.The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine ('Ecstasy') in healthy volunteers.Citalopram inhibits platelet function independently of SERT-mediated 5-HT transport.Hand-Motor Dysfunction in Depression: Characteristics and Pharmacological EffectsThe role of the psychiatrist in the treatment of alcoholic liver disease
P2860
Q21129108-4EBB1899-FE7F-4325-9961-0F48910D73EEQ27310769-BAAA8C7C-FC52-487B-8EA8-45118A354BA7Q28378938-92AF3015-FBFA-433E-9270-EE82B4AD97A0Q31036699-AEDF1A40-33E1-4BB7-85B7-0CF6F3D5213BQ33946527-71776E29-2E83-4245-B837-F1DD3592671DQ33948515-BD9B011A-1DDB-44DF-ADC6-30F2EB8B5DEBQ33995120-F8D8AD8F-E18C-46AC-B362-A0314F9243E6Q34016393-272F61CF-7A62-4BDB-A88F-83BAB4207610Q34251176-7DA27F27-360C-477B-BD06-E095109BA05DQ34714284-766D8C19-CC56-4F14-BC3F-A9AD3FE0DC8CQ35047176-E87B7454-EAA9-40FC-8333-71315D46F3A8Q35376254-C1C424F5-FCF6-4BFC-A6D3-DFA31D4E9D2BQ35825761-06BA60D2-1A04-4EF5-953A-D3B0687A64B9Q35841358-388EE194-635A-4095-ADC1-9A6D5E449E4AQ36662893-E960FBB2-5C98-43C6-A81D-A6E8D3177054Q37175817-3BE2EC50-FFE4-4960-B397-607D9973E4ECQ37718886-AA4183E2-CCBC-4AA0-8997-D24CD5E10558Q37742091-AE680470-75E7-490B-92B4-A23EA81CE77EQ41330335-1F87B4CF-7645-4113-9DE6-0C827528663EQ42605137-88CA5C5B-9284-44A7-84F5-C67F08D08B8FQ43076353-4FBC579C-2ADB-4CEC-AF53-2B8E09137290Q44362498-8B1E90F1-9F7F-4363-AF43-168CBA66458EQ45050962-318C990B-62A7-496D-81C3-AAE71F00D728Q45188834-3F74F183-8318-42F1-A048-8DC6031F4946Q46656633-B49EC497-44E6-4F7E-9396-1768D1440AF6Q48223386-6FDFD6DF-9732-48CB-8253-E21075B36CCCQ48645987-D1CA0D0D-93A3-4A6F-A622-6678305473A3Q50608286-FA760D51-7FDB-40BA-A1D3-1F27E1FF8F01Q51971591-5D78211D-FFCC-4F3D-BBB0-01A4017EEF01Q52689114-9604F966-C410-4207-B724-EBECED899C8BQ57411359-334A967B-5AE8-421F-A5DA-8D4D7DD7D2E2Q58440143-C1BE6312-5228-4849-9175-9F3C31E0A3BD
P2860
Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
Citalopram. A review of its ph ...... tential in depressive illness.
@ast
Citalopram. A review of its ph ...... tential in depressive illness.
@en
type
label
Citalopram. A review of its ph ...... tential in depressive illness.
@ast
Citalopram. A review of its ph ...... tential in depressive illness.
@en
prefLabel
Citalopram. A review of its ph ...... tential in depressive illness.
@ast
Citalopram. A review of its ph ...... tential in depressive illness.
@en
P1433
P1476
Citalopram. A review of its ph ...... tential in depressive illness.
@en
P304
P356
10.2165/00003495-199141030-00008
P577
1991-03-01T00:00:00Z
P6179
1036224065